Syngene International Sees Sharp Open Interest Surge Amid Prolonged Downtrend

Open Interest and Volume Dynamics

On 28 Jan 2026, Syngene International Ltd’s open interest (OI) in derivatives climbed to 18,147 contracts from 16,428 the previous day, marking an absolute increase of 1,719 contracts or 10.46%. This rise in OI was accompanied by a futures volume of 9,843 contracts, reflecting robust trading activity. The combined futures and options value stood at approximately ₹8,851.63 lakhs, with futures contributing ₹7,880.17 lakhs and options an overwhelming ₹4,164.19 crores in notional value, underscoring significant market participation.

The underlying stock price closed near a fresh 52-week low of ₹476.15, down 2.77% intraday and underperforming its healthcare services sector by 1.86%. Over the past ten trading sessions, Syngene has declined by 24.09%, a steep correction that has seen the stock trade below all key moving averages – 5-day, 20-day, 50-day, 100-day, and 200-day – signalling sustained bearish sentiment.

Investor Participation and Liquidity

Investor engagement has intensified, as evidenced by a delivery volume of 21.44 lakh shares on 27 Jan, surging 283.99% above the five-day average delivery volume. This spike in delivery volume indicates that investors are either liquidating positions or repositioning amid the downtrend. The stock’s liquidity remains adequate, with a trade size capacity of ₹3.02 crore based on 2% of the five-day average traded value, facilitating sizeable transactions without significant market impact.

Market Positioning and Directional Bets

The surge in open interest amid a declining price trend often signals that fresh positions are being established, potentially reflecting directional bets by market participants. In Syngene’s case, the 10.46% increase in OI alongside a 1.74% drop in the stock price suggests that traders may be initiating short positions or hedging existing long exposures. The substantial options notional value further indicates active hedging or speculative strategies, with put options likely gaining traction as protection against further downside.

Syngene’s Mojo Score has deteriorated to 28.0, with a downgrade from Sell to Strong Sell on 19 Jan 2026, reflecting a negative outlook based on fundamental and technical parameters. The market cap grade remains modest at 3, consistent with its small-cap status and heightened volatility. This downgrade aligns with the observed price weakness and increased bearish positioning in derivatives.

Sector and Benchmark Comparison

While Syngene has underperformed its healthcare services sector by 1.86% on the day and declined sharply over the past fortnight, the broader Sensex has advanced 0.43%, highlighting the stock’s relative weakness. This divergence underscores company-specific challenges or sentiment factors weighing on Syngene, rather than sector-wide headwinds. Investors should note that the healthcare services sector has generally remained resilient, making Syngene’s underperformance more pronounced.

Technical Indicators and Trend Analysis

The stock’s failure to hold above any major moving average signals a bearish technical setup. The 10-day consecutive fall and 24.09% loss over this period confirm strong selling pressure. The fresh 52-week low at ₹476.15 further cements the downtrend, with no immediate signs of reversal. The rising delivery volumes suggest that long-term holders may be exiting or reducing exposure, adding to downward momentum.

Implications for Investors

Given the strong sell rating and deteriorating technicals, investors should exercise caution with Syngene International Ltd. The rising open interest and volume suggest that the market consensus is increasingly bearish, with directional bets favouring further downside or volatility. Long-term investors may consider reducing exposure or hedging positions, while traders might explore short-selling opportunities or protective option strategies.

However, the healthcare services sector’s overall resilience and Syngene’s underlying business fundamentals should not be overlooked. Any positive developments or sector tailwinds could provide a catalyst for recovery, but for now, the risk-reward profile appears skewed towards caution.

Conclusion

Syngene International Ltd’s recent surge in open interest amid a sustained price decline highlights a market increasingly positioned for further weakness. The combination of technical breakdowns, negative mojo grading, and heightened derivatives activity paints a challenging near-term outlook. Investors and traders should monitor open interest trends and volume patterns closely, as these will provide critical clues on evolving market sentiment and potential directional shifts.

In the current environment, prioritising risk management and considering alternative investment opportunities within the healthcare sector or broader market may be prudent.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →